Global Proteomics Market Analysis
Proteomics-Market-Size
Proteomics-Market-Size
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Global</strong><br />
<strong>Proteomics</strong><br />
<strong>Market</strong> <strong>Analysis</strong><br />
June 2016<br />
Growth opportunities in a market in transition<br />
Growing demand for personalized medicine, and strong R&D<br />
investments in proteomics-based drug discovery projects has fueled<br />
the growth.
Executive Summary<br />
The global proteomics market has shown strong growth, and is<br />
expected to exceed $15 billion by 2020<br />
• <strong>Global</strong> market for <strong>Proteomics</strong> is forecast to exceed $15 billion by 2020,<br />
buoyed by growing demand for personalized medicine, and strong R&D<br />
investments in proteomics-based drug discovery projects.<br />
• Fueled by the importance of accurate and sensitive diagnosis offered by<br />
proteomics in the area of personalized medicine, the market for proteomics is<br />
expected to register strong growth in the coming years.<br />
• Detailed analysis of proteins provides better opportunities for the<br />
development of drugs that can target disease pathways more efficiently. The<br />
discovery of new protein biomarkers in disease development, and the<br />
corresponding development of novel drugs for cancer, cardiovascular, and<br />
neurodegenerative diseases have strengthened the market in recent years.<br />
Identification and characterization of proteins provides a deeper<br />
understanding of disease mechanisms when compared to genetic profiling.<br />
• Funding support offered by government and private organizations for<br />
proteomics research, developments in mass spectrometry-based proteomic<br />
and chemoproteomic strategies, and increased focus of biotechnology and<br />
pharmaceutical companies on novel drug discovery methods, bode well for<br />
the global proteomics market. Despite the opportunities for growth, the<br />
market will continue to face challenges such as tough regulatory approvals,<br />
dearth of qualified and skilled research manpower, and high cost of<br />
proteomics instruments and equipment.<br />
• The United States represents the largest market worldwide, followed by<br />
Europe. Emerging economies of Asia and Latin America are poised to fuel<br />
future growth in the market supported by socioeconomic growth, increased<br />
focus on biotechnological research, strong government support, and<br />
increased outsourcing of proteomics services to Asian countries.<br />
www.merkleandsears.com<br />
2014 2015 2016 2017 2018 2019 2020<br />
China<br />
Japan<br />
South Korea<br />
Taiwan<br />
India<br />
Australia<br />
Others<br />
<strong>Global</strong> proteomics market growth<br />
($ Billion)<br />
APAC proteomics market<br />
by Country (2015-2020)<br />
2
Executive Summary<br />
Strong growth curves ahead for many market segments<br />
• The US proteomics market benefits from the vast diversity and scale of<br />
operations of the academic sector. Further, ability of academics to reposition<br />
themselves into new groups in order to meet the scientific challenges in<br />
proteomics industry also proves beneficial for the industry. <strong>Proteomics</strong><br />
research, being complementary to genomic approaches, has been<br />
witnessing increased integration with drug discovery market. Rising interest<br />
in integrated technologies is driving rapid expansion of bio-informatics and<br />
protein biochip technologies in Europe.<br />
• The shift towards proteomics from genomics facilitates technological<br />
advancements, which are aimed at providing assistance to drug discovery<br />
researchers by offering enhanced throughput, resolution, and sensitivity,<br />
compared to conventional protein research tools.<br />
• Over the next decade, better understanding of proteome will lead to the<br />
development of advanced sequencing methods and superior technologies<br />
that help expand application possibilities.<br />
• Discovery of new biomarkers is expected to enable successful development<br />
of newer drugs. Technological improvements in instruments and workflow<br />
and miniaturization of biochip devices will create new milestones in diagnosis<br />
and drug development applications. Biomarker-based research will be a<br />
strong area of focus given the increasing importance of proteomics in novel<br />
drug discovery, design, and development.<br />
• Major players covered in the report include Bio-Rad Laboratories Inc.,<br />
ThermoFisher Scientific, Waters Corporation, Sigma-Aldrich Corporation,<br />
PerkinElmer Inc., Bruker Daltonics Inc., Caprion <strong>Proteomics</strong> Inc., GE<br />
Healthcare, and Shimadzu Biotech, among others.<br />
www.merkleandsears.com<br />
U.S.<br />
Canada<br />
Mexico<br />
Rest of<br />
North<br />
America<br />
North American proteomics market<br />
by application<br />
Aggregate<br />
2020 demand<br />
<strong>Market</strong> share breakdown, 2015<br />
xx%<br />
xx%<br />
xx<br />
xx<br />
xx<br />
xx<br />
Demand<br />
growth<br />
%, CAGR<br />
xx<br />
xx<br />
xx<br />
xx<br />
xx<br />
xx<br />
xx<br />
xx<br />
xx%<br />
3
<strong>Market</strong> <strong>Analysis</strong><br />
Two-dimensional electrophoresis continues to hog the limelight<br />
• Two-dimensional electrophoresis (2DE) is one of the most cost-effective protein<br />
profiling technologies. Using this technology, the constituents of a protein<br />
sample can be entirely visualized in a single gel.<br />
• The global economic recession affected the government research spending<br />
across the globe. However, it was a blessing in disguise for the 2DE industry as<br />
researchers were on the prowl for cheaper technologies in that cash-crunched<br />
climate. Participants in the market capitalized on the then prevailing situation to<br />
improve their revenues.<br />
• The 2DE market is projected to grow at very high rate in the near term, as<br />
academic researchers – the main consumers of these products – are<br />
increasingly investing more in cheaper alternatives for protein expression<br />
studies, such as 2DE. End users are more likely to automate their existing<br />
2DGE-MS process than invest in new technologies since the others have not<br />
been as successful on a wide range of samples.<br />
• Sample preparation solutions can vary dramatically from each other. Companies<br />
therefore find it very difficult to come out with sample preparation kits that will<br />
effectively address the varied needs of the market. A large number of products<br />
are required to address this market, but each of these products will enjoy only a<br />
limited response due to the differing needs of customers. Sample preparation is<br />
a major challenge that the industry needs to overcome. It affects both the<br />
reproducibility and the resolution of the 2DE experiment which, in turn,<br />
influences the end results.<br />
• As a result, many market players are increasingly focusing on determining the<br />
kinds of samples that are the most widely studied in the market. Following this, a<br />
feasibility analysis to check the financial viability of developing a sample<br />
preparation kit for such samples is conducted. This has helped these companies<br />
to more effectively fulfil varied sample requirements.<br />
www.merkleandsears.com<br />
C a p a c i t y<br />
Steep growth curve ahead for<br />
the market<br />
Current market<br />
position<br />
xx%<br />
xx%<br />
2016<br />
<strong>Market</strong> share breakdown, 2015<br />
Predicted strategic<br />
inflection point<br />
xx%<br />
4<br />
Time
<strong>Market</strong> <strong>Analysis</strong><br />
Growing adoption of integrated Liquid Chromatography systems<br />
• Increasing need to extract greater amounts of proteomic information is driving<br />
the adoption of Liquid Chromatography (LC). Interest and level of activity in<br />
the field of proteomics has remained high and will continue to increase<br />
because crucial information is mostly gathered from proteins.<br />
• Researchers are still on the lookout for the product that will enable them to<br />
draw information accurately and efficiently. As the study of proteins gains<br />
importance in other industries and research markets, the demand for protein<br />
LC technologies is expected to continue growing.<br />
• The superior capabilities of LC to analyze complex samples when coupled<br />
with mass spectrometry (MS) are propelling deployment of integrated LC<br />
systems.<br />
• Manufacturers, recognizing the needs of researchers working on advanced<br />
analysis, are striving to offer technologies such as fully integrated LC-MS<br />
systems.<br />
• These integrated solution systems are likely to provide researchers with<br />
sophisticated analysis tools offering higher ease of use. Sustained innovation<br />
is anticipated to further increase LC adoption.<br />
• However, limited volume of protein samples has restricted the number of LC<br />
experiments conducted so far. In many proteomics research programs,<br />
protein sample availability restricts liquid chromatography (LC) experiments.<br />
• Researchers are often unable to conduct the entire range of experiments<br />
desired since only small amounts of valuable protein samples are available.<br />
Answering numerous questions with limited sample is difficult. Moreover, with<br />
researchers often having to prioritize experiments, researchers are unable to<br />
conduct thorough studies.<br />
www.merkleandsears.com<br />
<strong>Global</strong> liquid chromatography market for<br />
protein studies<br />
$ Million<br />
2014 2015 2016 2017 2018 2019 2020<br />
<strong>Market</strong> share breakdown, 2015<br />
xx%<br />
xx%<br />
xx%<br />
5
<strong>Market</strong> <strong>Analysis</strong><br />
Growing need for automated crystallization shaping the protein<br />
crystallography market<br />
• Increasing demand for high throughput protein crystallography has resulted<br />
increase in adoption of automated crystallization. The need to understand<br />
exactly how small molecules bind to their protein target is driving the demand for<br />
protein crystallography in drug discovery. A higher throughput protein<br />
crystallography process requires protein crystallization to also become high<br />
throughput and this is best achieved through automated crystallization. A<br />
number of large proteomic initiatives are being launched, increasing market<br />
opportunities for automated crystallization.<br />
• Drug discovery initiatives have driven numerous technological advancements in<br />
structural proteomics. Pharmaceutical companies today acknowledge that<br />
structure discovery helps lead optimization. With rapid technology advances,<br />
structure-based design is set to become a preferred method for discovering new<br />
drugs.<br />
• As an increasing number of companies discover the importance and significance<br />
of protein structure studies for drug discovery, more efforts are being made<br />
toward improving structural determination technologies. <strong>Market</strong> consolidation<br />
and industrialization along with the introduction of powerful integrated systems is<br />
changing research approaches. Besides automation, miniaturization of protein<br />
crystals and processes including purification is another big trend.<br />
• Lack of experienced researchers has further fueled the demand for automated<br />
crystallization. Protein crystallization is a process that requires training, skill, and<br />
time. The number of trained researchers and people willing to commit to such a<br />
process has been decreasing. The surge in automation has addressed the<br />
worrisome dearth of protein-structure researchers. However, automation allows<br />
researchers with less experience and training to be involved in crystallization.<br />
This frees researchers, allowing them to focus on increasing productivity,<br />
reproducibility, and throughput.<br />
www.merkleandsears.com<br />
C a p a c i t y<br />
Steep growth curve ahead for<br />
the market<br />
Current market<br />
position<br />
xx%<br />
xx%<br />
2016<br />
<strong>Market</strong> share breakdown, 2015<br />
Predicted strategic<br />
inflection point<br />
xx%<br />
6<br />
Time
Industry <strong>Analysis</strong><br />
<strong>Global</strong> Industry Overview<br />
• Proteomic research inherently requires huge capital investments and<br />
historically, it has yielded poor revenues. Pharmaceutical companies have<br />
hesitated in adopting the proteomics technologies in their drug<br />
development pipeline as they have been wary of premium pricing.<br />
• However, today public funding institutions are giving importance to this<br />
growing biological discipline next to comparative genomics. The proteomics<br />
market is considered an emerging area with immense potential. In fact,<br />
Governments and federal ministries in three major European countries,<br />
namely the United Kingdom, France and Germany, have allocated thematic<br />
priorities to nurture the growth of this market. This has resulted in greater<br />
industrialization of this field, which in turn, has boosted the confidence of<br />
companies to invest in this fast-paced and dynamic arena. Low return on<br />
investment that can dissuade potential entrants in proteomics technology<br />
markets has thus been offset by increasing public funding.<br />
• The increasing relevance of protein-protein interactions and protein<br />
analytics in drug discovery as well as clinical diagnostics has highlighted<br />
the importance of proteome research. Technological advancements in<br />
protein separation technologies and two-dimensional gel electrophoresis<br />
are likely to usher in a ubiquitous approach to assess differential protein<br />
expressions. Maximum utility of expression proteomics tools in the target<br />
discovery phase of drug development is likely to trigger reliable separation<br />
and identification of low abundant proteins with poor expression levels.<br />
Moreover, the development of matrix-assisted laser desorption/ionization<br />
(MALDI) and electrospray ionization (ESI) technologies has enlarged the<br />
scope of building versatile mass spectrometers, considered the cornerstone<br />
of proteomics. The improved mass spectrometers are likely to have<br />
enhanced functionalities of automation and compatibility with other<br />
proteomics equipment.<br />
www.merkleandsears.com<br />
<strong>Global</strong> proteomics market<br />
$ Million<br />
2014 2015 2016 2017 2018 2019 2020<br />
<strong>Market</strong> share breakdown, 2015<br />
xx%<br />
xx%<br />
xx%<br />
7
Regional <strong>Analysis</strong><br />
European proteomics market overview<br />
• The European Union (EU) has become a popular hub for advanced research<br />
into proteomics. This can be attributed to the significant government funding at<br />
both the national level and from individual EU agencies.<br />
• Moreover, Europe houses some of the largest pharmaceutical companies that<br />
are extending their support to research programs related to proteomics, either<br />
in-house or in collaboration with smaller firms. The primary goal of most of<br />
these pharmaceutical companies is to go beyond the realms of human genome<br />
sequencing and expand the list of identified proteins and genes, which will<br />
ultimately aid in understanding disease mechanisms and developing<br />
corresponding therapeutics.<br />
• The high impact of emerging technologies such as proteomics is causing<br />
radical changes in the fields of drug discovery as well as clinical research and<br />
diagnostics. As a result, end users in the European life sciences arena are<br />
looking for a complete, integrated solution. The current trend in the European<br />
market has been the formation of broad partnerships, as the European<br />
commercial sector realizes that this is one of the best ways of maximizing<br />
opportunities in this area since smaller companies can affiliate themselves with<br />
larger, more recognized suppliers.<br />
• Increased funding for research and sustained pharmaceutical and<br />
biotechnology industry interest in drug discovery is a major growth factor for the<br />
European proteomics market. Though proteomics is a critical technology for<br />
mass screening and post-translational modification of proteins, the European<br />
proteomics industry's progress is restricted by complications faced by<br />
organizations in sourcing adequate funding for various research initiatives. The<br />
relative higher cost of equipment and software in the European market has<br />
enhanced the importance of funding to huge extent.<br />
www.merkleandsears.com<br />
European proteomics market<br />
$ Million<br />
2014 2015 2016 2017 2018 2019 2020<br />
<strong>Market</strong> share breakdown, 2015<br />
xx%<br />
xx%<br />
xx%<br />
8
Country <strong>Analysis</strong><br />
Government support has fueled the growth in Australian market<br />
• Growing focus on research has driven the growth in proteomics market in<br />
Australia. Extensive research in proteomics is promising cures for previously<br />
untreatable diseases. With the Government assisting by providing additional<br />
tax concessions, the spending on research and development (R&D) is likely to<br />
increase by 58.0 percent in 2016.<br />
• As a result, more than 300 biotechnology companies focusing on proteomics<br />
applications have set up operations in Australia to take advantage of this<br />
favorable environment. Drug discovery companies are also likely to have ample<br />
opportunities to slightly modify the lead compound in order to screen and<br />
exclude patients of a certain genotype who are more prone to developing<br />
certain side effects from clinical trials.<br />
• Australian research companies are increasingly entering into collaborations<br />
with Venture Capitalists for funds. Compared to Western countries, most of the<br />
Australian biotech companies are start-up undertakings that are in need of<br />
capital to support their research.<br />
• However, venture capitalists (VCs) have been hesitant to provide funds since<br />
these companies have few products in the final stages of drug discovery and<br />
have to wait for around ten years for their products to complete clinical trials<br />
before releasing them into the market.<br />
• The long gestation period and the low market awareness on the potential of<br />
biotech products have led to insufficient funding of the biotech ventures in<br />
Australia as investors perceive them as being too risky. However, the Australian<br />
government and the top research companies have helped the VCs to<br />
understand the commercial viability of their projects and the time required to<br />
market them. Their efforts have begun to bore fruits as the market has<br />
witnessed growing entries from several major international VCs in the recent<br />
years.<br />
www.merkleandsears.com<br />
VC funding in Australian proteomics market<br />
$ Million<br />
2014 2015 2016 2017 2018 2019 2020<br />
<strong>Market</strong> share breakdown, 2015<br />
xx%<br />
xx%<br />
xx%<br />
9
Growing Diabetic Population – A Key Growth Driver<br />
Prevalence of Diabetes in Million (2005 – 2015)<br />
Growing base of diabetic population and the acute need for their quality care and<br />
treatment is boosting the adoption of proteomics technologies in the stem cell research activities<br />
Million Million Million<br />
30<br />
25<br />
25<br />
25<br />
20<br />
15<br />
10<br />
5<br />
0<br />
20<br />
15<br />
10<br />
5<br />
0<br />
20<br />
15<br />
10<br />
5<br />
0<br />
U.S.<br />
Canada<br />
Brazil Mexico Argentina<br />
Peru Venezuela Chile<br />
Russia Turkey Poland<br />
Czech Republic<br />
Hungary<br />
Million<br />
25<br />
20<br />
15<br />
10<br />
5<br />
0<br />
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015<br />
Million<br />
140<br />
Belgium<br />
Netherlands 120<br />
Sweden 100<br />
Switzerland<br />
Portugal<br />
80<br />
Austria 60<br />
U.K<br />
Spain<br />
40<br />
France 20<br />
Italy<br />
0<br />
Germany<br />
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015<br />
www.merkleandsears.com<br />
New Zealand<br />
Hong Kong<br />
Taiwan<br />
Thailand<br />
Philippines<br />
Australia<br />
Malaysia<br />
Indonesia<br />
South Korea<br />
Japan<br />
China<br />
India<br />
10
Competition <strong>Analysis</strong><br />
Fourteen players identified as candidates for benchmarking as<br />
'Large Competition' given industry spread<br />
Frequency across market segments<br />
6<br />
xxxx<br />
xxxx<br />
xxxx<br />
4<br />
xxxx<br />
xxxx<br />
xxxx<br />
xxxx<br />
xxxx<br />
2<br />
xxxx<br />
xxxx<br />
xxxx<br />
xxxx<br />
0<br />
xxxx<br />
xxxx<br />
(2)<br />
Prominent players<br />
Emerging players<br />
(4)<br />
0 1 2 3 4 5 6<br />
Frequency across Regions<br />
Fourteen players defining the industry<br />
benchmark in 2015<br />
www.merkleandsears.com<br />
11
Thank you<br />
www.merkleandsears.com